---
title: "NHS Branded Medicines Tranche Framework for London and South of England"
ocid: "ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c"
markdown_url: "https://d3tenders.com/contract/ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c.md"
json_url: "https://d3tenders.com/contract/ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c.json"
source: "Contracts Finder"
current_stage: "Award"
buyer: "NHS ENGLAND"
published: "2024-08-20"
---

# NHS Branded Medicines Tranche Framework for London and South of England

Buyer: NHS ENGLAND  
Current stage: Award  
OCID: ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c.json)

## Summary

NHS England has concluded the award phase of a procurement process for the NHS Branded Medicines Tranche Framework, covering London and the South of England. This framework contract, valued at approximately £380.95 million, will commence on 1st September 2024 and spans multiple regions including London, the East Midlands, East of England, North East, North West, South East, South West, West Midlands, and Yorkshire and the Humber. The framework encompasses a variety of pharmaceutical products under the CPV classification 33600000 and was procured using an open procedure. Key suppliers involved in this award include Sun Pharma UK Ltd, Biogen, Merck Sharpe & Dohme (UK) Limited, and AstraZeneca, among others, with the framework running until 31st August 2026, having options for extension up to 24 months.

This procurement presents a significant opportunity for businesses in the pharmaceutical sector to collaborate with NHS England, potentially expanding their market reach and driving growth. The framework is suitable for Small and Medium-sized Enterprises (SMEs), offering them a substantial platform to supply branded medicines across a broad geographical and institutional scope. Businesses specializing in pharmaceutical manufacturing, distribution, and supply chain logistics will find this tender particularly lucrative, enabling them to secure long-term partnerships and establish a strong presence in the healthcare market within multiple UK regions.

## Notice

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Contracts Finder |
| Latest notice | https://www.contractsfinder.service.gov.uk/Notice/5804a973-6494-40b3-8ef1-7809f1927694 |
| Notice type | Award Notice |
| Procurement type | Standard |
| Procurement category | Goods |
| Procurement method | Open |
| Procurement method details | Open procedure (above threshold) |
| Tender suitability | SME |
| Awardee scale | Not specified |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 20 Aug 2024 |
| Submission deadline | 5 Apr 2024 |
| Future notice date | Not specified |
| Award date | 21 Jul 2024 |
| Contract period | 31 Aug 2024 - 31 Aug 2026 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | £380,950,720 |
| Lots value | Not specified |
| Awards value | £380,950,720 |
| Contracts value | Not specified |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Not specified |
| Awards status | Active |
| Contracts status | Not specified |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS ENGLAND |
| Locality | RUNCORN |
| Post town | Warrington |
| Postcode | WA7 2ES |
| Country | England |
| ITL 1 | TLD North West (England) |
| ITL 2 | TLD7 Merseyside |
| ITL 3 | TLD71 East Merseyside |
| Local authority | Halton |
| Electoral ward | Halton Lea |
| Westminster constituency | Runcorn and Helsby |
| Delivery location | TLC North East (England), TLD North West (England), TLE Yorkshire and The Humber, TLF East Midlands (England), TLG West Midlands (England), TLI London, TLJ South East (England), TLK South West (England) |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 29 |
| Supplier names | ACCORD-UK; ASTRAZENECA; AVENTIS PHARMA LTD T/A SANOFI; BIOGEN; BIOSIMILAR COLLABORATIONS IRELAND; CELLTRION HEALTHCARE UNITED KINGDOM; CHUGAI PHARMA; DR.REDDY'S LABORATORIES (UK; ELI LILLY; GALAPAGOS BIOTECH; GEDEON RICHTER; GLAXOSMITHKLINE; JANSSEN-CILAG; LEO PHARMA; MANX HEALTHCARE; MERCK SHARPE & DOHME (UK; NAPP PHARMACEUTICALS; NOVARTIS PHARMACEUTICALS; ORGANON PHARMACEUTICALS; ORIFARM; PFIZER; ROCHE PRODUCTS; SOBI (SWEDISH ORPHAN BIOVITRUM; SUN PHARMA; TAKEDA; TEVA; THORNTON AND ROSS; UCB PHARMA LTD (PRIMARY; ZENTIVA PHARMA |

## CPV Codes

### Divisions

- 33 - Medical equipments, pharmaceuticals and personal care products

### Codes

- 33600000 - Pharmaceutical products

## Release History

- 20 Aug 2024 at 14:46 - Award - Award Notice - https://www.contractsfinder.service.gov.uk/Notice/5804a973-6494-40b3-8ef1-7809f1927694

## Documents

- https://www.contractsfinder.service.gov.uk/Notice/5804a973-6494-40b3-8ef1-7809f1927694
  20th August 2024 - Awarded contract notice on Contracts Finder
- https://www.contractsfinder.service.gov.uk/Notice/Attachment/6f8ed3f3-9ef9-42d7-bef6-ef7fd307361b
  Transparency Award Schedules - London & South of England - CM_PHR_225689_02
- https://www.contractsfinder.service.gov.uk/Notice/Attachment/34661fa5-43e0-4aa4-8dc7-ce1c4cc4c42f
  Transparency Award Schedules - London & South of England - CM_PHR_225689_01
- https://www.contractsfinder.service.gov.uk/Notice/Attachment/32cdba8c-36ca-4dc9-8260-979b9e4c6261
  Transparency Award Schedules - Omalizumab and Diroximel Fumarate for MAE & NOFE - CM_PHR_225689_03
- https://www.contractsfinder.service.gov.uk/Notice/Attachment/f4fe1e61-36b9-4c9b-99ce-5bb8648c0d7b
  Parties Appointed to Framework Agreement -CM_PHR_22_5689 - London & South of England - 1st September 2024
- https://www.contractsfinder.service.gov.uk/Notice/Attachment/022879ad-43f7-4d37-8b80-1d967708d773
  Framework Agreement and Terms and Conditions - CM_PHR_22_5689 - London & South of England - 1st September 2024

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c.json.